Xeris Biopharma
XERS | NASDAQ
$16.70
+$0.04 (+0.24%)
At close: Nov 16, 2026, 4:00 PM ET
$16.49
-$0.21 (-1.26%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Xeris Biopharma Company Profile
Company profile explainedCompany Profile
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
Key Executives
| Name | Position |
|---|---|
| John Shannon | Chairman & CEO |
| Beth Hecht | Chief Legal Officer & Corporate Secretary |
| Kevin McCulloch | President & Chief Operating Officer |
| Steven Pieper | Chief Financial Officer |
| Allison Wey | Senior Vice President of Investor Relations & Corporate Communications |
| Anh Nguyen | Chief Medical Officer |
| Brian Conner | SVP of Quality and Chief Compliance & Risk Officer |
| Joshua Bennett | Vice President of Strategy & Business Development |
| Kendal Korte | Senior Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 30, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 14, 2026 | 8-K | Current Report |
| Oct 02, 2026 | 4 | Filing |
| Oct 02, 2026 | 4 | Filing |
| Oct 02, 2026 | 4 | Filing |
| Sep 29, 2026 | 4 | Filing |
| Sep 09, 2026 | 8-K | Current Report |
| Sep 01, 2026 | 4 | Filing |
| Sep 01, 2026 | 4 | Filing |
| Sep 01, 2026 | 4 | Filing |
Xeris Biopharma
| Country | United States |
| IPO Date | Jun 21, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 435 |
| CEO | John Shannon |
Contact Details
1375 West Fulton Street Chicago,
Illinois 60607 United States
Stock Details
| Ticker Symbol | XERS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001867096 |
| CUSIP Number | 98422E103 |
| ISIN Number | US98422E1038 |
| SIC Code | 2834 |
Recent News
- 4 days ago / seekingalpha.comXeris Biopharma: Time For A Pause
- 10 days ago / marketbeat.comXeris Biopharma Q3 Earnings Call Highlights
- 11 days ago / seekingalpha.comXeris Biopharma Holdings, Inc. (XERS) Q3 2026 Earnings Call Transcript
- 12 days ago / zacks.comXeris Biopharma (XERS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
- 24 days ago / gurufocus.comXeris Biopharma Holdings Inc (XERS) Stock Down 6.1% but Still Overvalued -- GF Score: 66/100
- 26 days ago / businesswire.comXeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026
- 2 months ago / reuters.comLundbeck expresses interest in buying Xeris, Bloomberg News reports
- 2 months ago / seekingalpha.comXeris Biopharma Holdings, Inc. (XERS) Discusses XP-8121 Program Overview, Phase 3 Study Details and Commercial Strategy Transcript
- 3 months ago / businesswire.comXeris Announces Details for XP-8121 Program Overview Webinar
- 3 months ago / seekingalpha.comXeris Biopharma: A Commercial Stage Pharma That May Be A Slow-Burn Buy Opportunity
Add to Watchlist
Select watchlists to add or remove XERS